Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis: A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle
Table 4
Base case incremental analysis.
6-month costs
Incremental efficacy of PASI 75 response
ICER (costs per additional PASI 75 responder)
Etanercept
$17,954
55%
Dominated
Adalimumab
$13,429
63%
$21,315a
Ustekinumab 45 mg
$16,787
67%
$83,950b
Infliximab
$19,725
71%
$68,175c
Ustekinumab 90 mg
$33,574
72%
$1,384,900d
Incremental efficacy of PGA 0/1 response
ICER (costs per additional PGA 0/1 responder)
Adalimumab
$13,429
56%
$23,980a
Ustekinumab 45 mg
$16,787
58%
$167,900b
Etanercept
$17,954
58%
Dominated
Ustekinumab 90 mg
$33,574
62%
$3,358,150c
Infliximab
$19,725
69%
$26,709c
Compared to placebo.
bCompared to adalimumab.
cCompared to ustekinumab 45 mg.
dCompared to infliximab.